ETHNOPHARMACOLOGICAL RELEVANCE: From seeds of Carapa guianensis the Amazon native people extracts the andiroba oil, which is traditionally used as febrifuge, anti-malarial, insecticidal and repellant. The non-saponifiable fraction separated from the oil is rich in limonoids, which assigns its pharmacological effects. MATERIALS AND METHODS: The andiroba oil and its limonoid-rich fraction were submitted to in vitro antiplasmodial bioassay using W(2) and Dd(2) strains of Plasmodium falciparum. The acute toxicity of andiroba oil was evaluated. The limonoid-rich fraction was subjected to fractionation and identified its major constituents. RESULTS: Andiroba oil and its limonoid-rich fraction inhibited the growth of W(2) clone in 100%, between 24 and 72 h, at concentrations of 8.2 μg/mL and 3.1 μg/mL, respectively. Under the same conditions, the parasitaemia of Dd(2) clone provoked by the andiroba oil showed inhibition of 31% (IC(50) >82 μg/mL) with a time-dependent relationship of 24h and inhibition of 88% (IC(50) 8.4 μg/mL) after 72 h, while for the limonoid-rich fraction the inhibition of Dd(2) clone was 56% (IC(50) 2.8μg/mL) at 24h and 82% (IC(50) 0.4 μg/mL) after 72 h. Andiroba oil in acute toxicity test with a fixed dose (LD(50) >2000 mg/kg) was not toxic The limonoids identified in the oil were gedunin, 6α-acetoxygedunin, 7-deacetoxy-7-oxogedunin, 7-deacetylgedunin, 1,2-dihydro-3β-hydroxy-7-deacetoxy-7-oxogedunin and andirobin. Gedunin and derivatives has been reputed as anti-malarials. CONCLUSION: The results support the traditional use of andiroba oil as antiplasmodial, which additionally proved not to be toxic in bioassays conducted with mice.
ETHNOPHARMACOLOGICAL RELEVANCE: From seeds of Carapa guianensis the Amazon native people extracts the andiroba oil, which is traditionally used as febrifuge, anti-malarial, insecticidal and repellant. The non-saponifiable fraction separated from the oil is rich in limonoids, which assigns its pharmacological effects. MATERIALS AND METHODS: The andiroba oil and its limonoid-rich fraction were submitted to in vitro antiplasmodial bioassay using W(2) and Dd(2) strains of Plasmodium falciparum. The acute toxicity of andiroba oil was evaluated. The limonoid-rich fraction was subjected to fractionation and identified its major constituents. RESULTS:Andiroba oil and its limonoid-rich fraction inhibited the growth of W(2) clone in 100%, between 24 and 72 h, at concentrations of 8.2 μg/mL and 3.1 μg/mL, respectively. Under the same conditions, the parasitaemia of Dd(2) clone provoked by the andiroba oil showed inhibition of 31% (IC(50) >82 μg/mL) with a time-dependent relationship of 24h and inhibition of 88% (IC(50) 8.4 μg/mL) after 72 h, while for the limonoid-rich fraction the inhibition of Dd(2) clone was 56% (IC(50) 2.8μg/mL) at 24h and 82% (IC(50) 0.4 μg/mL) after 72 h. Andiroba oil in acute toxicity test with a fixed dose (LD(50) >2000 mg/kg) was not toxic The limonoids identified in the oil were gedunin, 6α-acetoxygedunin, 7-deacetoxy-7-oxogedunin, 7-deacetylgedunin, 1,2-dihydro-3β-hydroxy-7-deacetoxy-7-oxogedunin and andirobin. Gedunin and derivatives has been reputed as anti-malarials. CONCLUSION: The results support the traditional use of andiroba oil as antiplasmodial, which additionally proved not to be toxic in bioassays conducted with mice.
Authors: Tiago B Pereira; Luiz F Rocha E Silva; Rodrigo C N Amorim; Márcia R S Melo; Rita C Zacardi de Souza; Marcos N Eberlin; Emerson S Lima; Marne C Vasconcellos; Adrian M Pohlit Journal: Malar J Date: 2014-08-13 Impact factor: 2.979
Authors: Flávia L M Jesus; Fernanda B de Almeida; Jonatas L Duarte; Anna E M F M Oliveira; Rodrigo A S Cruz; Raimundo N P Souto; Ricardo M A Ferreira; Regina Gendzelevski Kelmann; José C T Carvalho; Ana C Lira-Guedes; Marcelino Guedes; Conxita Solans; Caio P Fernandes Journal: Evid Based Complement Alternat Med Date: 2017-07-17 Impact factor: 2.629
Authors: Carlos F Araujo-Lima; Andreia S Fernandes; Erika M Gomes; Larisse L Oliveira; Andrea F Macedo; Rosemar Antoniassi; Allan E Wilhelm; Claudia A F Aiub; Israel Felzenszwalb Journal: Oxid Med Cell Longev Date: 2018-05-02 Impact factor: 6.543